webinar register page

Webinar banner
Updates on Biomarkers and Therapeutics for People with Down Syndrome and Alzheimer's Disease: What you need to know.
Many people with Down syndrome will show signs of decline as they age, often associated with the presence of Alzheimer's disease. These signs often begin in their early 50s and will affect their lives and health. Worry and concern about this disease and its implications for self-care, supports, health, and quality of life can be very unsettling.

The recent news of new medications that may hold promise in making a difference for persons diagnosed with Alzheimer's disease needs clarification, perspective, and an understanding of how they may help adults with Down syndrome, and possibly adults with other intellectual disabilities.

The NTG is pleased to bring together a national panel of expert researchers and practitioners in the field of Down syndrome and Alzheimer's disease who will engage in a realistic and thoughtful discussion of both current and future therapeutics, matters related to diagnostics, and the emerging research on biomarkers. We see this webinar as useful to parents and families, providers, advocates, clinicians, practitioners, and others invested in the future for persons with Down syndrome. Come join us, listen, and engage our panelists with your questions.

This webinar is free to the public. The webinar will be recorded and a link to the recording sent to all registered participants unable to attend the live webinar following the webinar.

5:00 pm EDT
4:00 pm Central Time
3:00 pm Mountain Time
2:00 PM Pacific Daylight Time
11:00 AM Hawaii-Aleutian Standard Time

Oct 7, 2021 05:00 PM in Eastern Time (US and Canada)

Webinar logo
* Required information
Loading

Speakers

Michael S. Rafii, MD, PhD
Medical Director of the Alzheimer’s Therapeutic Research Institute and Associate Professor of Neurology @Keck School of Medicine
Dr. Raffi is a physician-scientist whose research program focuses on understanding the genetic form of Alzheimer's disease that occurs in persons with Down syndrome. He is Principal Investigator of the NIH-funded Alzheimer’s Clinical Trials Consortium - Down Syndrome (ACTC-DS). He is also editor of the textbook ‘Common Pathogenic Mechanisms between Down Syndrome and Alzheimer's Disease: Steps toward Therapy' and serves as a scientific reviewer for the NIH and the Alzheimer's Association. His work has been featured in the New York Times, Chicago Tribune, Wall Street Journal and National Public Radio (NPR).
Brian A. Chicoine MD
Medical Director @Advocate Medical Group Adult Down Syndrome Center
Brian Chicoine, MD is the Medical Director of the Adult Down Syndrome Center in Park Ridge, IL. He is on the faculty of Family Medicine at Advocate Lutheran General Hospital. Dr. Chicoine is co-founder of the Adult Down Syndrome Center which has served and documented the health and psychosocial needs of over 6000 adolescents and adults with Down syndrome since its inception in 1992. Dr. Chicoine graduated from Loyola University of Chicago Stritch School of Medicine and completed his Family Medicine residency at Lutheran General Hospital. He co-authored two books Mental Wellness of Adults with Down Syndrome and The Guide to Good Health for Teens and Adults with Down Syndrome published by Woodbine House Press. Dr. Chicoine has provided medical care for adults with intellectual disabilities for over 30 years and has presented and written extensively on caring for adults with Down syndrome.
Elizabeth Head, MD
Professor and Vice Chair for Research in the Department of Pathology and Laboratory Medicine @University of California, Irvine
Dr. Head is a neuroscientist and Director of the Experimental Pathology Program at the Gillespie Neuroscience Research Facility at the University of California, Irvine. Educated at the University of Toronto, Canada, she the Co-Principal Investigator at the Alzheimer Biomarker Consortium - Down Syndrome (ABC-DA) and Core Lead REC, Co-Investigator of the neuropathology and Down syndrome cohort core at the University of California's Alzheimer's Disease Center. She is the author of numerous articles in the neuroscience of dementia and Down syndrome and the recipient of a number of grants from the National Institute of Health..
James Hendrix, PhD
Chief Scientific Officer @LuMind™ Research Down Syndrome Foundation
Dr. Hendrix has more than two decades of industry and non-profit experience in the life sciences, with a strong track record in drug development, establishing partnerships and promoting research awareness for neuroscience and Alzheimer’s disease. Prior to joining LuMind Dr. Hendrix served as Director of Global Science Initiatives for the Alzheimer’s Association, where he provided leadership on specific domestic and international efforts focused on advancing the Association’s science agenda. A critical element of his role was the management of industry consortia such as the Alzheimer’s Association Research Roundtable (AARR); the Global Biomarker Standardization Consortium; and assisting with the coordination of the $100M Imaging Dementia—Evidence for Amyloid Scanning (IDEAS) Study on the clinical usefulness of amyloid PET imaging.
Seth Keller, MD
Co-President @National Task Group on ID & Dementia Practices
Seth M. Keller, MD, a board-certified neurologist in private practice with Advocare Neurology of South Jersey and specializes in the evaluation and care of adults with Intellectual and Developmental Disabilities (I/DD) with neurologic complications. He cares for individuals with I/DD both in the community as well in New Jersey’s ICF/DD centers. Dr. Keller is on the Executive Board of the Arc of Burlington County as well as on the board for The Arc of New Jersey Mainstreaming Medical Care board. Dr. Keller is the Past President of the American Academy of Developmental Medicine and Dentistry (AADMD) and is the co-president of the National Task Group on Intellectual Disabilities and Dementia Practices (NTG). Dr. Keller is also the director of the Adults with I/DD Special Interest Group in the American Academy of Neurology (AAN). He is actively involved in national and international I/DD health education as a speaker and webinar and workshop participant.
Kathy Service, RN, MS, FNP-BC, CDDN
Nurse Practitioner @National Task Group on ID & Dementia Practices
Ms. Service is a nurse practitioner and specializes in gerontological nursing. Retired from the Massachusetts Department of Developmental Services, she consults as a dementia care specialist advanced practice provider. She has served on various advisory boards and committees, including the founding board of DDNA and presented and authored articles on aging, dementia, end-of-life related to people with intellectual disability.
Lucille Esralew, PhD
Webinar Moderator, Senior Psychologist @California Department of Developmental Services and the National Task Group on ID & Dementia Practices
Dr. Lucille Esralew has been a practicing neuropsychologist since 1995. She has been on the faculty of Rutgers (continuing education), volunteer faculty at Rowan School of Osteopathic Medicine, and has been Contributing Faculty for Walden University since 2014 in the School of Psychology. She has over twenty years experience as a diagnostician, psychotherapist, clinical supervisor eighteen years experience as a Program Director/Ciinical Administrator involved in the development of crisis services, inpatient psychiatric care and community-based follow along for children and adults with intellectual and developmental disorders and co-occurring mental health disorders.